C4 Therapeutics (CCCC) Assets Average (2020 - 2026)

C4 Therapeutics' Assets Average history runs 7 years deep, the most recent figure standing at $344.0 million for Q1 2026.

• On a quarterly basis, Assets Average rose 2.81% year-over-year to $344.0 million in Q1 2026; TTM through Mar 2026 was $344.0 million, a 2.81% increase from a year earlier, with the FY2025 full-year figure at $354.3 million, down 2.39% from the prior year.
• Assets Average climbed to $344.0 million in Q1 2026 per CCCC's latest filing, from $312.3 million in the prior quarter.
• Across five years, Assets Average topped out at $511.1 million in Q1 2022 and bottomed at $281.0 million in Q3 2025.
• The 5-year median for Assets Average is $378.6 million (2024), against an average of $385.0 million.
• Across the five-year window, Assets Average surged 32.05% in 2022 and retreated 25.78% in 2023, its largest moves.
• Year by year, Assets Average stood at $446.1 million in 2022, then declined by 20.49% to $354.7 million in 2023, then increased by 2.28% to $362.8 million in 2024, then decreased by 13.93% to $312.3 million in 2025, then rose by 10.15% to $344.0 million in 2026.
• Per Business Quant, the three latest CCCC Assets Average figures stand at $344.0 million (Q1 2026), $312.3 million (Q4 2025), and $281.0 million (Q3 2025).